(Adds details throughout) By Deena Beasley July 23 (Reuters) - The U.S. Department of Justice on Thursday said it will not stand in the way of efforts by companies, including Eli Lilly and Co and Amgen Inc , to share information to help scale up capacity to manufacture antibody treatments for COVID-19, the disease caused by the new coronavirus.The drugmakers are in various stages of developing experimental monoclonal antibodies - manufactured proteins designed to bind to a targeted cell, neutralize it and mark it for destruction by the immune system - for treatment, or even prevention, of COVID-19.